Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...